Some studies have reported that subcutaneously implanted Pan02 tumor-bearing mice respond significantly well to anti-PD-1/PD-L1 and anti-CTLA-4 antibody treatment [45,46,47]. This evidence concerns the gene CTLA4 and neoplasm.